2022 Q1 Form 10-Q Financial Statement
#000156459022019318 Filed on May 10, 2022
Income Statement
| Concept | 2022 Q1 | 2021 Q4 | 2021 Q1 |
|---|---|---|---|
| Revenue | $8.766M | $3.737M | $4.360M |
| YoY Change | 101.06% | -27.44% | -38.42% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $6.775M | $6.688M | $4.110M |
| YoY Change | 64.84% | 115.05% | 23.8% |
| % of Gross Profit | |||
| Research & Development | $19.36M | $21.89M | $16.31M |
| YoY Change | 18.7% | 46.21% | 38.34% |
| % of Gross Profit | |||
| Depreciation & Amortization | $376.0K | $270.0K | $200.0K |
| YoY Change | 88.0% | 35.0% | 100.0% |
| % of Gross Profit | |||
| Operating Expenses | $19.36M | $28.58M | $20.42M |
| YoY Change | -5.18% | 58.14% | 35.11% |
| Operating Profit | -$17.37M | ||
| YoY Change | |||
| Interest Expense | -$2.695M | -$242.0K | $230.0K |
| YoY Change | -1271.74% | -141.02% | -30.3% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.695M | ||
| YoY Change | |||
| Pretax Income | -$20.06M | -$25.08M | -$15.83M |
| YoY Change | 26.73% | 103.24% | 111.52% |
| Income Tax | -$394.0K | $484.0K | -$68.00K |
| % Of Pretax Income | |||
| Net Earnings | -$19.67M | -$25.56M | -$15.76M |
| YoY Change | 24.78% | 107.5% | 110.64% |
| Net Earnings / Revenue | -224.39% | -684.08% | -361.56% |
| Basic Earnings Per Share | -$0.35 | ||
| Diluted Earnings Per Share | -$352.1K | -$458.9K | -$428.0K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 54.85M | ||
| Diluted Shares Outstanding | 54.85M |
Balance Sheet
| Concept | 2022 Q1 | 2021 Q4 | 2021 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $537.9M | $551.8M | $274.7M |
| YoY Change | 95.83% | 211.74% | 19.59% |
| Cash & Equivalents | $116.5M | $175.7M | $87.99M |
| Short-Term Investments | $421.4M | $376.1M | $186.7M |
| Other Short-Term Assets | $4.753M | $4.481M | $3.500M |
| YoY Change | 35.8% | 49.37% | 34.62% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $2.923M | $2.765M | $5.100M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $545.6M | $559.0M | $283.3M |
| YoY Change | 92.59% | 207.52% | 21.12% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $12.24M | $4.466M | $6.900M |
| YoY Change | 77.33% | 25.66% | 130.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $207.0K | $465.0K | $500.0K |
| YoY Change | -58.6% | -7.0% | 150.0% |
| Total Long-Term Assets | $12.44M | $12.99M | $7.400M |
| YoY Change | 68.15% | 75.43% | 138.71% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $545.6M | $559.0M | $283.3M |
| Total Long-Term Assets | $12.44M | $12.99M | $7.400M |
| Total Assets | $558.1M | $572.0M | $290.7M |
| YoY Change | 91.97% | 202.35% | 22.66% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.659M | $3.824M | $2.100M |
| YoY Change | -21.0% | 27.47% | -34.38% |
| Accrued Expenses | $6.041M | $10.38M | $5.600M |
| YoY Change | 7.88% | 29.75% | 12.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $7.982M | $14.32M | $11.50M |
| YoY Change | -30.59% | -3.11% | -76.29% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $8.224M | $7.652M | $2.900M |
| YoY Change | 183.59% | 146.84% | 480.0% |
| Total Long-Term Liabilities | $8.224M | $7.652M | $2.900M |
| YoY Change | 183.59% | 146.84% | 480.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $7.982M | $14.32M | $11.50M |
| Total Long-Term Liabilities | $8.224M | $7.652M | $2.900M |
| Total Liabilities | $16.21M | $21.97M | $14.40M |
| YoY Change | 12.54% | 23.23% | -70.67% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$377.0M | -$357.4M | -$294.3M |
| YoY Change | 28.13% | 28.32% | |
| Common Stock | $919.9M | $900.7M | |
| YoY Change | 103.26% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $541.9M | $550.0M | $276.3M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $558.1M | $572.0M | $290.7M |
| YoY Change | 91.97% | 202.35% | 22.66% |
Cashflow Statement
| Concept | 2022 Q1 | 2021 Q4 | 2021 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$19.67M | -$25.56M | -$15.76M |
| YoY Change | 24.78% | 107.5% | 110.64% |
| Depreciation, Depletion And Amortization | $376.0K | $270.0K | $200.0K |
| YoY Change | 88.0% | 35.0% | 100.0% |
| Cash From Operating Activities | -$18.43M | -$20.71M | -$20.71M |
| YoY Change | -11.01% | 57.97% | 58.44% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $212.0K | -$514.0K | -$400.0K |
| YoY Change | -153.0% | -38.07% | -38.46% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$48.68M | -$214.9M | -$54.70M |
| YoY Change | -11.01% | -588.23% | 4.63% |
| Cash From Investing Activities | -$48.89M | -$215.4M | -$55.10M |
| YoY Change | -11.28% | -598.69% | 4.11% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 7.876M | 324.0M | 118.7M |
| YoY Change | -93.37% | 647806.0% | 15.86% |
| NET CHANGE | |||
| Cash From Operating Activities | -18.43M | -20.71M | -20.71M |
| Cash From Investing Activities | -48.89M | -215.4M | -55.10M |
| Cash From Financing Activities | 7.876M | 324.0M | 118.7M |
| Net Change In Cash | -59.15M | 87.81M | 42.98M |
| YoY Change | -237.63% | 191.34% | 20.2% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$18.43M | -$20.71M | -$20.71M |
| Capital Expenditures | $212.0K | -$514.0K | -$400.0K |
| Free Cash Flow | -$18.64M | -$20.20M | -$20.31M |
| YoY Change | -8.21% | 64.46% | 63.51% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2022Q1 | us-gaap |
Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
|
Unlimited | |
| CY2022Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2022Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2022Q1 | us-gaap |
Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
|
Unlimited | |
| CY2022Q1 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
||
| CY2022Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2022Q1 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| CY2022Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2022Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2022Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P10Y3M | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y3M | |
| CY2022Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M10D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y6M10D | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
605000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
7652000 | |
| CY2022Q1 | us-gaap |
Liabilities
Liabilities
|
16206000 | |
| CY2022Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2022Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
53059049 | |
| CY2022Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
53059049 | |
| CY2022Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
800307000 | |
| CY2022Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
119580000 | |
| CY2022Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-377044000 | |
| CY2022Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-990000 | |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
541853000 | |
| CY2022Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
558059000 | |
| CY2022Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
8766000 | |
| CY2022Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
19360000 | |
| CY2022Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6775000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4109000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
20417000 | |
| CY2022Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
368000 | |
| CY2022Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-3362000 | |
| CY2021Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
155000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-15832000 | |
| CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-68000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15764000 | |
| CY2021Q1 | xene |
Net Income Loss Available To Preferred Stockholders Basic
NetIncomeLossAvailableToPreferredStockholdersBasic
|
423000 | |
| CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-15341000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.42 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36824619 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
118615000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
106000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
276277000 | |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19670000 | |
| CY2022Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
142000 | |
| CY2021Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
9000 | |
| CY2021Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-74000 | |
| CY2022Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
258000 | |
| CY2022Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-3362000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3213000 | |
| CY2021Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-74000 | |
| CY2022Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
299000 | |
| CY2022Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-20064000 | |
| CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-394000 | |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19670000 | |
| CY2022Q1 | xene |
Net Income Loss Available To Preferred Stockholders Basic
NetIncomeLossAvailableToPreferredStockholdersBasic
|
299000 | |
| CY2022Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19371000 | |
| CY2022Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.35 | |
| CY2022Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
54852792 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
171355000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15764000 | |
| CY2022Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
7876000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1965000 | |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7876000 | |
| CY2022Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
293000 | |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-59147000 | |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
175688000 | |
| CY2022Q1 | xene |
Interest Received
InterestReceived
|
1682000 | |
| CY2021Q1 | xene |
Interest Received
InterestReceived
|
651000 | |
| CY2022Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
203000 | |
| CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
202000 | |
| CY2022Q1 | xene |
Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
|
1529000 | |
| CY2021Q1 | xene |
Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
|
448000 | |
| CY2022Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-377044000 | |
| CY2022Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of presentation:</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are presented in U.S. dollars.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one wholly-owned subsidiary as of March 31, 2022, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on December 2, 2016.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation. Certain information has been reclassified to conform with the financial presentation adopted for the current year.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2021 included in the Company’s 2021 Annual Report on Form 10-K filed with the SEC and with the securities commissions in British Columbia, Alberta and Ontario on March 1, 2022.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited interim consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company included in the Company’s 2021 Annual Report on Form 10-K for the year ended December 31, 2021. </p> | |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18428000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20708000 | |
| CY2022Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
212000 | |
| CY2022Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
68956000 | |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-48888000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-55104000 | |
| CY2022Q1 | xene |
Proceeds From Issuance Of Common Shares And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonSharesAndPreFundedWarrantsNetOfIssuanceCosts
|
7876000 | |
| CY2021Q1 | xene |
Proceeds From Issuance Of Common Shares And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonSharesAndPreFundedWarrantsNetOfIssuanceCosts
|
118615000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
106000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
118721000 | |
| CY2021Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
67000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
42976000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
45009000 | |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
116541000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
87985000 | |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19670000 | |
| CY2022Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
238000 | |
| CY2021Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
139000 | |
| CY2022Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
192000 | |
| CY2021Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
184000 | |
| CY2022Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0342 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0245 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
682000 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
942000 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
985000 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1040000 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1095000 | |
| CY2022Q1 | xene |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
6868000 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
11612000 | |
| CY2022Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1904000 | |
| CY2022Q1 | xene |
Future Lease Incentives Reasonably Certain Of Use
FutureLeaseIncentivesReasonablyCertainOfUse
|
1484000 | |
| CY2022Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8224000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1111950 | |
| CY2022Q1 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
1659000 | |
| CY2021Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
3824000 | |
| CY2022Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2106000 | |
| CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5940000 | |
| CY2022Q1 | xene |
Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
|
3780000 | |
| CY2021Q4 | xene |
Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
|
3550000 | |
| CY2022Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
155000 | |
| CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
285000 | |
| CY2022Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
282000 | |
| CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
118000 | |
| CY2022Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
7982000 | |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13717000 | |
| CY2021Q4 | xene |
Warrants Exercise Description
WarrantsExerciseDescription
|
The Company may not affect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. | |
| CY2021Q1 | xene |
Warrants Exercise Description
WarrantsExerciseDescription
|
The Company may not affect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. | |
| CY2022Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
2775996 | |
| CY2021Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
1081081 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5638232 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1659845 | |
| CY2022Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
219107 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
122403 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
3897 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
5936 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7075073 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5742608 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3231657 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2769438 | |
| CY2022Q1 | xene |
Stock Options Exercised For Number Of Common Shares For Cash
StockOptionsExercisedForNumberOfCommonSharesForCash
|
0 | |
| CY2021Q1 | xene |
Stock Options Exercised For Number Of Common Shares For Cash
StockOptionsExercisedForNumberOfCommonSharesForCash
|
46296 | |
| CY2022Q1 | xene |
Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
|
149311 | |
| CY2021Q1 | xene |
Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
|
36159 | |
| CY2022Q1 | xene |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
219107 | |
| CY2021Q1 | xene |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
76107 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0194 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0115 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.70 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.68 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
19.23 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.86 |
